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Introduction
The establishment and sensitive detection of blood biomarkers that can be used as a reliable approach for the screening of neurodegenerative conditions such as Alzheimer's disease (AD) in a clinical setting continues to be a major challenge. 1, 2 Currently, the cost and time involved in diagnosing AD and other neurodegenerative conditions remains a major hurdle in tackling a condition which is rapidly increasing in priority for society. 3 Efforts by researchers are hampered by a lack of accurate and sensitive analytical techniques capable of molecularspecific measurements in blood samples along with the growing need to compare the levels of different biomarker populations simultaneously. Amyloid- peptides and Tau proteins are consistently reported as promising serum biomarker candidates for AD patients along with a range of peripheral marker candidates connected to immunological mechanisms, inflammation and oxidative stress, and protein signaling pathways are also of interest. [4] [5] [6] In the case of Tau protein, increased levels in AD patient plasma has been reported, 7 however varying overlap in concentrations between different patient categories has prevented a plasma-based clinical screening tool being established.
Despite the limitations of the conventional enzyme-linked immunosorbent assay (ELISA)
format, 8, 9 there have been very few alternative approaches reported capable of the rapid and direct detection of Tau in plasma. Recently, a single molecule ELISA digital array technology 10 has been applied to the detection of femotmolar levels of Tau in blood. Surface plasmon resonance (SPR) has also been used to quantify the interaction between different Tau forms and antibodies 11, 12 as well as study DNA-Tau interactions, 13 however no SPR measurements in plasma have been reported. Nanoparticles have been applied to create a localized SPR 14 sensor as well as surface-enhanced Raman scattering 15 and multi-photon scattering 16 even fewer number report analysis in plasma without significant dilution in buffer prior to measurement. 26 Recently, we reported a new sandwich assay for another potential biomarker for AD, -1 antitrypsin (AAT). 27 As the native concentration of AAT is ~40 M, these measurements involved significant serum dilution in buffer prior to analysis. However, such an approach is not feasible for protein targets like Tau where concentrations in healthy patients can be in the femtomolar range. 7 Thus, after establishing the DNA aptamer/Tau 381/antiTau sandwich assay performance in buffer, we also describe a robust methodology for the quantitative detection of Tau in plasma at clinically relevant concentrations. To achieve this, various mixed monolayer surface chemistries were compared in the optimization of the SPR chip as well as a series of non-specific controls simultaneously acquired on the same chips.
Conventional ELISA measurements were also performed to support our results.
5
Experimental Section
More extensive information on the materials used and the protocols related to SPR chip preparation, protein detection and also ELISA measurements are provided in the Supporting
Information. In short, all in-situ SPR bioaffinity measurements were performed using a Biacore An overview of the sandwich assay developed for plasma based detection is provided in Fig.   1 . The SPR gold chip was first modified with a mixed monolayer of 11-mercaptoundecanoic acid (MUA) and 11-mercaptoundecanol (MUD). 33 Both the Tau specific DNA aptamer and control sequences were covalently coupled to MUA via a 5' end NH2 modification and EDC/NHSS linking chemistry. Tau specific adsorption measurements were first performed in buffer to establish the binding affinity of the DNA aptamer before progressing to measurements 7 in plasma. Further enhancement of the SPR detection signal is then achieved by subsequently flowing antiTau (suspended in buffer) across the chip surface resulting in the formation of the surface sandwich complex. The covalent coupling of the DNA aptamer to the SPR chip surface is preferred to antibody coupling when there is a choice between both options. This is due to the better control over the probe molecule surface attachment, packing densities and nonspecific adsorption behavior that can be achieved using aptamer functionalization compared to antibody probes. 27, 34 Tau 381 is one of six known variants ranging from 352 to 441 amino acids in length. 35 The relative abundance and molecular mechanism of each variant is still poorly understood and commercially available ELISA kits do not differentiate between variants, suggesting common epitope sites for antibody pairs across all species. For our investigation, we focused on tau 381 The utilization of mixed MUA:MUD monolayers was then explored. The motivation for this is based on recent reports that this approach promotes reduced non-specific adsorption of proteins, 37 plus DNA, peptide 33 which is important for successful measurements in biofluids.
A systematic study of the SPR sensing performance and also non-specific binding of bovine serum on mixed MUA:MUD layers has also been reported by Booksh et al, 38 which highlighted the improvements that can be achieved using MUD. Shown in MUA:40% MUD and 60% MUA:40% PEG. In all three curves, the maximum signal change associated with the 100% MUA surface is used for normalization.
Sandwich Assay:
The formation of the surface sandwich assay was also first investigated in buffer solution using SPR chips prepared with different mixed monolayer compositions. The normalized R.U. values shown in Fig. 3 were obtained by acquiring the average R.U.
signals associated with specific target binding and subtracting this from an average of the nonspecific control signals, NC1 to NC4. These are summarized in Table 1 , and involve repeat measurements in the absence of Tau (NC1), using a different target protein (CFH, NC2), replacing antiTau with anti-CFH (NC3) or instead using a different aptamer sequence (NC4).
For every data point presented in Fig. 3 
Measurements in Plasma:
Having established the Tau assay in buffer for different mixed monolayer compositions we then performed a series of SPR measurements directly in plasma alongside comparative measurements using a commercial ELISA sandwich assay kit and plate reader. Based on the optimization measurements described above, the antiTau concentration for the SPR sandwich assay was fixed at 100 nM to enable femtomolar detection levels since the Tau concentration in normal patient plasma samples has been recently reported as low as 60-170 fM, respectively. 7 The measurement dynamic range was further tuned by utilizing either 60% MUA:40% MUD or 40% MUA:60% MUD or 60% MUA:40% PEG monolayer surfaces. (Figs. 4a, 4d, 4g ) it can be seen that both the spiked and non-spiked data curves are both consistently higher than the negative control data curves (see Fig. S7 for additional comparative plots). As expected, the R.U. signals for Tau-spiked plasma were consistently higher than the equivalent measurements performed in buffer. In order to clearly demonstrate the relative contributions of both non-specific adsorption of plasma proteins and also the specific adsorption of Tau to the larger signal, both R.U. (Figs. 4b, 4e, 4h ) and normalized R.U. (Figs. 4c, 4f, 4i ) plots were calculated. The results of linear fitting both are shown in Table S1 (supporting information) alongside the same analysis for the equivalent measurements performed in buffer earlier.
The slope values for both the 60% MUA:40% MUD and 40%
MUA:60% MUD spiking data sets show agreement between the plasma and buffer measurements. This indicates that the increase in the raw R.U. signal associated with nonspecific adsorption is generally uniform across all measurements and that the relative increases in signal between data points is due to a higher spiked Tau concentration. However, the 60% MUA:40% PEG monolayer (Figs. 4g , h, i) exhibited a more limited concentration range where a linear response was observed. There was also a significant difference in the linear slope fits between the plasma and buffer data series for PEG (see Table S1 , supporting information) as well as poorer SPR signal reproducibility, further highlighting the better performance of MUD compared to PEG. This is maybe due to the fact that the tightly and uniformly packed selfassembled monolayer of MUD mixed with MUA blocks nonspecific adsorption sites on the gold surface more effectively without impeding specific interactions. value is comparable with the only previous report that we are aware of that utilizes a sensitive analytical technique capable of demonstrating low femtomolar concentration levels of the target tau protein present in the plasma of healthy patients. 7 In addition, it is interesting to note that for the 60% MUA chip, ~45% of the SPR response was associated with Tau specific adsorption compared to ~57% for the 40% MUA chip. Along with changes in surface probe density, this also contributes to the differences in the linear response range and SPR signal offsets observed between the two chips.
A final set of Tau detection measurements in both buffer and plasma were performed using a commercial ELISA kit and compared with the SPR surface sandwich assay. The ELISA results are shown in the supporting information (Fig. S8) . A linear response detection range was obtained for spiked concentrations ranging from 2 pM to 80 pM in both buffer and plasma 15 solutions with very close overlap in sensing performance in both environments. However, the ELISA performance was not sensitive enough to detect Tau present in non-spiked plasma.
Further calibration assays were also performed comparing the use of the Tau provided by the ELISA kit manufacturer or instead using the same Tau 381 utilized in the SPR measurements.
Interestingly, a steeper response slope was obtained for the Tau solution provided with the ELISA kit but no significant signal was detected below 2 pM in either case. These measurements highlight the limited sensing performance of ELISA while SPR can be successfully applied to perform plasma diagnostics of native biomarker concentrations in the low femtomolar region. The improved performance of SPR compared to ELISA is associated with combination of several factors including better control over surface chemistry and nonspecific adsorption on the SPR chip and the use of continuous flow microfluidics beneficial at low target concentrations rather than static wells. A secondary binding step involving the formation of the sandwich assay is required to achieve SPR sensitivities in the fM range and the fact that this can be achieved directly for SPR while avoiding the larger errors associated with the enzymatic amplification reaction needed for ELISA signal transduction is also a significant advantage. 
Conclusions
In this article, a novel DNA aptamer-antibody sandwich assay specific to Tau protein biomarker has been developed and successfully applied for femtomolar concentration analysis in human plasma using surface plasmon resonance. The SPR chip surface chemistry was optimized via a series of experiments utilizing different ratios of a mixed monolayer of two differently terminated alkanethiols followed by the covalent coupling of the DNA aptamer in order to reduce the level of non-specific interactions while maintaining the analytical performance of the proposed surface sandwich assay. Robust control over the surface chemistry in combination with multi-channel measurement capability for simultaneous control measurements is essential for measurements in biological fluids such as plasma. Also, comparative measurements using ELISA for Tau analysis in plasma highlighted that the SPR based sandwich assay is a more sensitive option. As more important disease biomarkers are discovered and the corresponding nucleic acid aptamers selected, it is envisioned that the use of multiplexed SPR will continue to become more prevalent for medical diagnostics in biofluids.
